Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. - Wikidata - awgldk - TriplyDB

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

http://www.wikidata.org/entity/Q42260141

about

Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)Towards the targeted management of Chediak-Higashi syndrome Hemophagocytic lymphohistiocytosis: review of etiologies and management How we treat chronic active Epstein-Barr virus infection.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis.Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review.Adult hemophagocytic lymphohistiocytosis causing multi organ dysfunction in a patient with multiple autoimmune disorders: when the immune system runs amok.PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.Hemophagocytic lymphohistiocytosis (HLH): a review of literature.Updates on histiocytic disorders.Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis.Hereditary and acquired hemophagocytic lymphohistiocytosis.Transplantation in rare lymphoproliferative and histiocytic disorders.Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis (HLH).Liver transplantation for children with acute liver failure associated with secondary hemophagocytic lymphohistiocytosis.Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.Hemophagocytic lymphohistiocytosis in a patient with Sjögren's syndrome: case report and review.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults.Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes.Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis.Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause.Familial Hemophagocytic Lymphohistiocytosis Presenting as Hydrops Fetalis.Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis.Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL.Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis.T cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents Haemophagocytic Lymphohistiocytosis manifestations.Two Brothers with Atypical UNC13D-Related Hemophagocytic Lymphohistiocytosis Characterized by Massive Lung and Brain Involvement.

P2860

Q26744508-7DD53A8F-42BD-459C-ABC9-23089F4585C5 Q26751532-F3BBF75B-F290-4D96-9C85-29ED80FDBA4B Q26829320-68E86325-4B05-446E-9849-E67E86F1F7CF Q26830538-8C526505-ADEB-4A91-BE80-909C842233B0 Q30235902-C993905D-06DB-4677-B7D7-96E5AB529FD0 Q33429617-71BA6EB8-0172-4592-BBE4-23961F665F0E Q33558135-8DA308EC-D532-43C0-868E-96AACD072A8D Q33905447-9A590159-6EA3-45EA-8171-B8B9E2F65E0F Q35800864-AB663A5D-E857-47EA-ACC8-CC0CB229C21C Q36253959-D8E19305-C5E8-40B4-BC47-9DEF67100852 Q36369924-0AA93B27-4499-4414-9D57-4F4699A7F902 Q36530710-3749683D-D578-47ED-8997-6ED9F79FCDEC Q37243949-905738C4-7055-4038-879E-D851A0BC09AB Q37277020-E39F12FA-9EB3-40A8-A7C2-0E11918888D2 Q38150694-2A045FB6-FF6F-4F49-9FEF-F2ED515CE3B4 Q38194538-F761D4C6-F52C-4DE6-9C99-1800B73E8E9B Q38229212-D1EB8D88-4057-498D-8A03-323CF41DDF44 Q38259614-17E4A849-D73D-44C1-899C-37B004C8DBC4 Q38259618-6AC707C3-D9EF-4E57-AF2B-D607720284D3 Q38267068-069440AA-5093-4021-B62F-4FFDDF6B4A24 Q38637780-15EF5EF9-66A7-4A18-8EDE-FB3D5AD8CCF1 Q38731504-DE15CC00-9C87-41D8-A8E0-1733834CD117 Q38842547-2DDF449F-31A2-4FC4-B19B-037BA8A5DAE2 Q38992336-2DC8E190-1627-432E-91FF-19C2508A6808 Q39010639-44EED13A-3D17-4789-8AFE-4445E1BFFCC3 Q39016299-1D9F08BC-6B90-4795-A85A-4E490BFFD773 Q39117038-6B716F68-9541-4C4B-BB11-939938BA80A9 Q39144075-FB211B11-B0E5-4765-9B89-316A3E979EF2 Q39378276-73BFAF55-83F5-4D77-A356-D61D83A9E3C4 Q39722802-382F1C63-D665-462D-82F3-A6AAA652491C Q40176181-E72C1665-A940-48F4-981D-D1246E693711 Q40519555-6A14D7D9-C83E-46A2-8AC9-E93A9B4D5467 Q40972864-C99DFBB1-DE1B-4833-8A6A-6A5759468C6A Q41597088-D908BB08-D61B-450F-BCD7-03222FA9FB04 Q41606389-4DE6AB5C-B6AA-4A86-A05B-FFAD3469B5B8 Q41923461-1765CC0A-E4E2-4C06-AE94-DF70E5347D26 Q47143695-140991FC-52DA-4162-8543-2CC0700FD427 Q47550133-FDD6C01A-9471-48F7-8C2E-AD475540891B Q47550593-BE3B0BDF-4826-4A5D-8DCD-FAE03D497B83 Q47875965-06D6DA87-822D-4D4E-92E1-C35C1534A4A9

P2860

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

http://www.wikidata.org/entity/Q42260141

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@en

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@nl

type

label

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@en

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@nl

prefLabel

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@en

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

@nl

P1433

Q42260141-ECFE3D79-CB4C-44DF-8190-E4E64642EE9D

P1476

Q42260141-F18A1A7D-F83F-4735-81C6-1F166833A423

P2093

Q42260141-1EEE6C38-4C46-4E23-BD76-0A8D5655C7D3

Q42260141-2C463834-BA90-419A-8D85-19FE35CDD1AE

Q42260141-3FF3246B-D954-4E46-9603-3F7AD0DA9E47

Q42260141-4BF4E5AD-EC6B-4F30-99E4-E70D1AE4590F

Q42260141-77FAA5DE-3E11-493F-BF37-1E228D850EFC

Q42260141-825F6A4E-3C9C-4CBD-B786-2E6468E889F5

Q42260141-827A5AA7-DE63-4978-9365-64CD044F29DD

Q42260141-9C74A395-BFB2-4F9B-9FFC-6D3BCA1DB949

Q42260141-BC230806-1000-414B-B27E-0DC98419A43E

Q42260141-CA38CA34-8689-46EB-B7DB-E1F774CBBCE3

P2860

Q42260141-01E270A7-A74E-439C-A489-521EC31C63C3

Q42260141-0C0DB6D9-DC89-4A4A-91BE-44102A0B8DDC

Q42260141-18CD4A08-D5B2-4AEA-8A1E-D017EB9B7163

Q42260141-228A6753-2178-442A-8A63-6D4FF9047AF8

Q42260141-335B6E6F-25C0-42AF-8DED-5217D8EE3EFC

Q42260141-352C5A76-433B-4BDF-965F-0ABEC8E53622

Q42260141-4B36777B-976D-4E62-8680-9B58DCCD16BE

Q42260141-4C774198-5F22-41A3-B57D-6C85542DCA54

Q42260141-6542CA68-8B6D-4D95-A6EC-B7C1C6113740

Q42260141-6EFFFFB8-2AFA-4566-A93D-C1F6408AA36F

P304

Q42260141-B2DC7809-B352-41DF-B45C-B670F2FDA585

P31

Q42260141-AB2E8C3D-B834-4039-BA80-F7B1062FEDAC

P356

Q42260141-C80833F7-9EA2-49FE-AEA1-9B249F6DCB52

P433

Q42260141-8040750F-0351-4947-BF53-A833F470E0C0

P478

Q42260141-30F24F0D-4332-4A34-BA43-67049521590A

P50

Q42260141-1F03043C-BAC3-4F14-B677-D9D190CB6636

Q42260141-ECA8AEF0-9E06-4078-96EB-2069C9B298C6

P577

Q42260141-FE92C5E7-B993-41A4-AAF3-D5A181534B4C

P698

Q42260141-F84561E5-B17B-4BB6-A9AA-4A5EEA283AE9

P932

Q42260141-B0B7CDC9-F392-4CB7-A8B5-CA8683D0DE3B

P356

P1433

Pediatric Blood & Cancer

P1476

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab

@en

P2093

Alexandra H Filipovich

http://www.w3.org/2001/XMLSchema#string

Carl E Allen

http://www.w3.org/2001/XMLSchema#string

Jack J Bleesing

http://www.w3.org/2001/XMLSchema#string

Joanna L Weinstein

http://www.w3.org/2001/XMLSchema#string

Julia Lawrence

http://www.w3.org/2001/XMLSchema#string

Julie Kanter

http://www.w3.org/2001/XMLSchema#string

Jun Q Mo

http://www.w3.org/2001/XMLSchema#string

Michael B Jordan

http://www.w3.org/2001/XMLSchema#string

Nadine D Lee

http://www.w3.org/2001/XMLSchema#string

Rebecca A Marsh

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients.

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis.

Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.

Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.

An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.

P304

101-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24188

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth L McClain

P577

2012-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22522603

http://www.w3.org/2001/XMLSchema#string

P932

3410971

http://www.w3.org/2001/XMLSchema#string